Warner Pharmaceuticals: Controlling Shareholder Transfers 8.44% Stake for 388 Million, No Change in Actual Control

LightningPacketLoss · 2026-03-24T19:33:23+00:00

Warner Pharmaceuticals announces that its controlling shareholder intends to transfer 11.08 million shares (8.44%) of unrestricted circulating shares to a concerted action party through an agreement transfer. The transfer price is 35.05 yuan/share, with a total consideration of 388 million yuan. This transfer will not change the shareholding ratio of the controlling shareholder and the concerted action party. The purpose is to optimize the shareholding structure and family asset planning, and requires compliance confirmation from relevant institutions.

LightningPacketLoss

2026-03-24 19:33:23

Abstract generation in progress

On March 24, Warner Pharmaceutical announced that its controlling shareholder, Hunan Warner Medical Investment Partnership (Limited Partnership), plans to transfer 11.08 million unrestricted circulating shares (representing 8.44% of the company’s total share capital) to an affiliated party, Hunan Warner Zhi Zhen Industry Investment Partnership (Limited Partnership), through an agreement transfer.

The announcement states that this equity change will not affect the total shareholding or proportion of the company’s controlling shareholder and affiliated parties, does not involve increasing or decreasing shareholdings, and does not trigger a mandatory tender offer. The transfer price for this agreement is 35.05 yuan per share, with a total transfer consideration of 388 million yuan.

Prior to the transfer, Warner Medical held 52.24 million shares, accounting for 39.78% of the total share capital. After the transfer, its holdings decrease to 41.16 million shares, representing 31.34%. Hunan Warner Zhi Zhen will hold 11.08 million shares after the transfer, accounting for 8.44% of the total share capital. The purpose of this transfer is to optimize the shareholding structure and facilitate family asset planning.

This equity change is subject to approval of compliance confirmation from the Shanghai Stock Exchange and registration of share transfer with China Securities Depository and Clearing Co., Ltd. Shanghai Branch, and there are uncertainties involved.

(Warner Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.